⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Official Title: A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Study ID: NCT01778439

Interventions

OMP-52M51

Study Description

Brief Summary: This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of California, San Francisco/Helen Diller Cancer Institute, San Francisco, California, United States

University of Colorado Denver -RCI-South Tower, Aurora, Colorado, United States

Karmanos Cancer Institute (KCI), Detroit, Michigan, United States

Wayne State University/Oncology Karmanos Cancer Institute, Detroit, Michigan, United States

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: